A

mid ongoing criticism that some states continue to curb access to hepatitis C drugs, Colorado officials have lifted restrictions that determined when patients could receive treatment. Going forward, Medicaid beneficiaries will no longer have to demonstrate an advanced stage of liver disease to be treated.

In explaining their decision, state officials pointed to declining costs for the medicines, which have dropped in price recently as more new drugs become available. Over the summer, AbbVie (ABBV) introduced a treatment that costs $26,400, before rebates and discounts, for an eight-week regimen, which is significantly less than the $84,000 that Gilead Sciences (GILD) charged for 12 weeks of treatment for Sovaldi when it was first marketed four years ago.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy